Epoetin delta is effective for the management of anaemia associated with chronic kidney disease

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2507-2513

  Spinowitz, Bruce S ^a,c   Pratt, Raymond D ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b SHIRE   (United States)

^c Nephrology Associates   (United States)

Author keywords

Chronic kidney disease; Clinical trial; Epoetin delta; Erythropoietin; Haemodialysis; Randomized controlled trial

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33845965338     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X158048     Document Type: Conference Paper

References (19)

1. McClellan WM. The epidemic of renal disease - what drives it and what can be done? Nephrol Dial Transplant 2006;21:1461-4
2. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10
3. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9
4. Ofsthun N, Labrecque J, Lacson E, et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-14
5. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34
6. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003;18(Suppl 2):ii7-12
7. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996;27:548-56
8. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin [Cooperative Multicenter EPO Clinical Trial Group]. J Am Med Assoc 1990;263:825-30
9. Lu WX, Jones-Burton C, Zhan M, et al. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005;101:c79-86
10. Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin < 10g/dL. Kidney Int 2005;68:788-95
11. Rossert J, Froissart M, Jacquot C. Anemia management and chronic renal failure progression. Kidney Int Suppl 2005;99: S76-S81
12. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28(Suppl 8):7-14
13. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001;98:3626-34
14. Shahrokh Z, Flatman S, Davies M, et al. M. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic N-glycolylneuraminic acid residues. Haematologica/The Hematology Journal 2006;91(Suppl 1):208
15. Varki A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol 2001;(Suppl 33):54-69
16. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 2005;175:228-36
17. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002;9:376-81
18. Miwa Y, Kobayashi T, Nagasaka T, et al. Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation? Xenotransplantation 2004;11:247-53
19. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14(Suppl 5):1-50